Fusion Pharmaceuticals
109 articles about Fusion Pharmaceuticals
-
Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights
1/6/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today reported continued progress across its pipeline of target alpha therapies (TATs) and provided recent corporate highlights.
-
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
1/5/2023
Fusion Pharmaceuticals Inc., and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc., announced that the companies have entered into a preferred partner agreement for the supply of actinium-225.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023
1/4/2023
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 38,000 shares of its common stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 07, 2022
12/7/2022
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 13,200 shares of its common stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 09, 2022
11/9/2022
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 104,000 shares of its common stock to four employees outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates
11/8/2022
Fusion Pharmaceuticals Inc. today announced financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate developments.
-
Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer
11/7/2022
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2022
10/5/2022
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 195,000 shares of its common stock to five employees outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 13, 2022
9/13/2022
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 197,200 shares of its common stock to 10 employees outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
9/7/2022
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced that the Company will present in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 12:55 p.m. ET.
-
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3
8/29/2022
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced that the first patient has been dosed in the Phase 1/2 study evaluating [225Ac]-FPI-1966 (FPI-1966) in patients with advanced solid tumors expressing fibroblast growth factor receptor three (FGFR3).
-
Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates
8/9/2022
Fusion Pharmaceuticals Inc. today announced financial results for the second quarter ended June 30, 2022 and provided an update on clinical and corporate developments.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022
8/2/2022
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 44,800 shares of its common stock to two employees outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 07, 2022
7/7/2022
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 37,200 shares of its common stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1
6/23/2022
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) applications for [ 225 Ac]-FPI-2059.
-
Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434
6/14/2022
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced the presentation of imaging data from the "cold antibody sub-study" evaluating pre-administration of cold antibody (naked antibody without the isotope) prior to administration of the imaging agent (antibody with the isotope) in the Phase 1 study of FPI-1434 for the treatment of solid tumors expressing IGF-1R.
-
Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement
6/10/2022
Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion's existing supply as company expands pipeline of actinium-based radio pharmaceuticals.
-
Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs
6/9/2022
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced updates on its Phase 1 clinical trial evaluating FPI-1434 as a monotherapy for the treatment of solid tumors expressing IGF-1R and its Phase 1 clinical trial evaluating FPI-1966 for the treatment of solid tumors expressing FGFR3.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 08, 2022
6/8/2022
Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 36,000 shares of its common stock to three employees outside Fusion's 2020 Stock Option and Incentive Plan.
-
Fusion Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference
6/6/2022
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2022 Jefferies Global Healthcare Conference.